XBI250103P100500
- 9.15
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Natera Shares Are Trading Higher After Canaccord Genuity Raised Its Price Target on the Stock From $165 to $180.
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
The S&P 500's 10 Worst Performing Stocks in 2023 Fell Again in 2024
Natera Analyst Ratings
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Best and Worst Performing S&P 500 Stocks in a Rosy Year for Index
Santa Claus Came Without Rallying the Troops | Live Stock
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
17 Analysts Assess Biogen: What You Need To Know
Piper Sandler Downgrades Biogen to Neutral, Lowers Price Target to $138
Biogen Analyst Ratings
How Is The Market Feeling About United Therapeutics?
Peering Into Moderna's Recent Short Interest
Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Why Did Pfizer's Exit From the Gene Therapy Program Hit Sangamo Hard?
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Here Are Morgan Stanley's Key Oncology Catalysts for 2025